<DOC>
	<DOCNO>NCT01917149</DOCNO>
	<brief_summary>Dilated cardiomyopathy ( DCM ) poorly understood cause systolic heart failure common indication heart transplantation worldwide . Despite advance medical device therapy , 5-year mortality patient DCM remain high . Patients diagnose dilate cardiomyopathy NYHA functional class II IV leave ventricular ejection fraction ( LVEF ) &lt; 35 % select randomize control study efficacy safety high dose Renin-angiotensin system ( RAS ) inhibitor ( benazepril valsartan ) , comparison low dose RAS inhibitor ( benazepril valsartan ) standard beta-adrenergic blocker therapy ( metoprolol ) . The primary endpoint cause death admission heart failure . Additional prespecified outcome include all-cause death , cardiovascular death , all-cause admission , heart failure admission . Secondary cardiovascular outcome include change baseline last available observation treatment NYHA functional class , quality-of-life score , LVEF , LVEDD , mitral regurgitation wall-motion score index assess ECG . Adverse event report in-hospital observation follow-up .</brief_summary>
	<brief_title>Supramaximal Titrated Inhibition RAAS Dilated Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Benazepril</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Diagnosis dilate cardiomyopathy Left ventricular ejection fraction &lt; 35 % NYHA Functional class IIIV Symptomatic rapidly deteriorate 1 month enrollment Signed informed consent Contradictions intolerance study drug : supine systolic arterial blood pressure &lt; 90 mmHg , renal artery stenosis &gt; 50 % , pregnancy lactation , impaired renal function ( estimate glomerular filtration rate &lt; 60 ml/min/1.73m2 , impair liver function ( total bilirubin &gt; 2 time upper limit normal , serum aspartate AST alanine ALT &gt; 3 time upper limit normal ) , hemoglobin less 8 mg/dl , hyperkalaemia ( serum potassium &gt; 5.5mmol/l ) , obstructive lung disease , advance atrioventricular block , comorbidity impact survival , know intolerance benazepril , valsartan metoprolol succinate ; HF secondary know cause : coronary artery disease base coronary angiography ( ≥50 % stenosis ≥1 major coronary artery ) and/or history myocardial infarction angina pectoris , acute subacute stage myocarditis , primary valve disease , diabetes mellitus , excessive use alcohol illicit drug ; Expected perform cardiac resynchronization therapy heart transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Dilated cardiomyopathy</keyword>
	<keyword>High dose ACEI/ARB</keyword>
</DOC>